| Intelligent image-activated cell sorting N Nitta, T Sugimura, A Isozaki, H Mikami, K Hiraki, S Sakuma, T Iino, ... Cell 175 (1), 266-276. e13, 2018 | 480 | 2018 |
| Label-free chemical imaging flow cytometry by high-speed multicolor stimulated Raman scattering Y Suzuki, K Kobayashi, Y Wakisaka, D Deng, S Tanaka, CJ Huang, C Lei, ... Proceedings of the National Academy of Sciences 116 (32), 15842-15848, 2019 | 162 | 2019 |
| Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer S Matsusaka, K Chìn, M Ogura, M Suenaga, E Shinozaki, Y Mishima, ... Cancer science 101 (4), 1067-1071, 2010 | 159 | 2010 |
| Raman image-activated cell sorting N Nitta, T Iino, A Isozaki, M Yamagishi, Y Kitahama, S Sakuma, Y Suzuki, ... Nature communications 11 (1), 3452, 2020 | 144 | 2020 |
| Effects of Peripheral Cannabinoid Receptor Ligands on Motility and Polarization in Neutrophil-like HL60 Cells and Human Neutrophils*♦ R Kurihara, Y Tohyama, S Matsusaka, H Naruse, E Kinoshita, T Tsujioka, ... Journal of biological chemistry 281 (18), 12908-12918, 2006 | 124 | 2006 |
| Virtual-freezing fluorescence imaging flow cytometry H Mikami, M Kawaguchi, CJ Huang, H Matsumura, T Sugimura, K Huang, ... Nature communications 11 (1), 1162, 2020 | 107 | 2020 |
| Role of C–KitReceptor Tyrosine Kinase in Development of Oval Cells in the Rat 2–Acetylaminofluorene/Partial Hepatectomy Model S Matsusaka, T Tsujimura, A Toyosaka, K Nakasho, A Sugihara, ... Hepatology 29 (3), 670-676, 1999 | 104 | 1999 |
| Circulating tumor cells as a surrogate marker for determining response to chemotherapy in Japanese patients with metastatic colorectal cancer S Matsusaka, M Suenaga, Y Mishima, R Kuniyoshi, K Takagi, Y Terui, ... Cancer science 102 (6), 1188-1192, 2011 | 89 | 2011 |
| A practical guide to intelligent image-activated cell sorting A Isozaki, H Mikami, K Hiramatsu, S Sakuma, Y Kasai, T Iino, T Yamano, ... Nature protocols 14 (8), 2370-2415, 2019 | 83 | 2019 |
| Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101) S Matsusaka, A Nashimoto, K Nishikawa, A Miki, H Miwa, K Yamaguchi, ... Gastric Cancer 19, 839-851, 2016 | 78 | 2016 |
| Sequentially addressable dielectrophoretic array for high-throughput sorting of large-volume biological compartments A Isozaki, Y Nakagawa, MH Loo, Y Shibata, N Tanaka, DL Setyaningrum, ... Science advances 6 (22), eaba6712, 2020 | 62 | 2020 |
| Pharmacogenomics of fluorouracil-based chemotherapy toxicity S Matsusaka, HJ Lenz Expert opinion on drug metabolism & toxicology 11 (5), 811-821, 2015 | 57 | 2015 |
| Circulating tumor cell (CTC) count and epithelial growth factor receptor expression on CTCs as biomarkers for cetuximab efficacy in advanced colorectal cancer Y Kuboki, S Matsusaka, S Minowa, H Shibata, M Suenaga, E Shinozaki, ... Anticancer Research 33 (9), 3905-3910, 2013 | 56 | 2013 |
| The role of oval cells in rat hepatocyte transplantation S Matsusaka, A Toyosaka, K Nakasho, T Tsujimura, A Sugihara, ... Transplantation 70 (3), 441-446, 2000 | 56 | 2000 |
| Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study M Suenaga, N Mizunuma, S Matsusaka, E Shinozaki, M Ozaka, M Ogura, ... Drug design, development and therapy, 3099-3108, 2015 | 55 | 2015 |
| Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer M Suenaga, T Mashima, N Kawata, T Wakatsuki, Y Horiike, S Matsusaka, ... Oncotarget 7 (23), 34811, 2016 | 51 | 2016 |
| Optical coherence tomography-based tissue dynamics imaging for longitudinal and drug response evaluation of tumor spheroids I Abd El-Sadek, A Miyazawa, LTW Shen, S Makita, S Fukuda, ... Biomedical Optics Express 11 (11), 6231-6248, 2020 | 50 | 2020 |
| Circulating endothelial progenitors and CXCR4‐positive circulating endothelial cells are predictive markers for bevacizumab S Matsusaka, Y Mishima, M Suenaga, Y Terui, R Kuniyoshi, N Mizunuma, ... Cancer 117 (17), 4026-4032, 2011 | 48 | 2011 |
| Angiotensin II type-1 receptor blockers enhance the effects of bevacizumab-based chemotherapy in metastatic colorectal cancer patients H Osumi, S Matsusaka, T Wakatsuki, M Suenaga, E Shinozaki, ... Molecular and clinical oncology 3 (6), 1295-1300, 2015 | 46 | 2015 |
| Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results … Y Sunakawa, S Stintzing, S Cao, V Heinemann, C Cremolini, A Falcone, ... Annals of Oncology 26 (12), 2450-2456, 2015 | 44 | 2015 |
